NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癲癇藥的全球市場

Epilepsy Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 993153
出版日期 內容資訊 英文 276 Pages
商品交期: 最快1-2個工作天內
價格
癲癇藥的全球市場 Epilepsy Drugs
出版日期: 2021年04月01日內容資訊: 英文 276 Pages
簡介

全球癲癇藥的市場規模,預計在分析期間(2020年∼2027年)將以3.3%的年複合成長率增長,從2020年的46億美元,到2027年達到58億美元。

本報告所分析的市場區隔之一的第1代,在分析期間中預計將以2.5%的年複合成長率增長,達到14億美元。

本報告提供全球癲癇藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Laboratories, Inc.
  • Cephalon, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi Aventis S.A.
  • Shire PLC
  • Tansna Therapeutics, Inc.
  • UCB Pharma, Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP21737

Abstract:

Global Epilepsy Drugs Market to Reach $5.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Epilepsy Drugs estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$5.8 Billion by 2027, growing at a CAGR of 3.3% over the analysis period 2020-2027. First Generation, one of the segments analyzed in the report, is projected to record a 2.5% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Second Generation segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 5.2% CAGR

The Epilepsy Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 5.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Third Generation Segment to Record 3.9% CAGR

In the global Third Generation segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.2 Billion in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$752.6 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories, Inc.
  • Cephalon, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi Aventis S.A.
  • Shire PLC
  • Tansna Therapeutics, Inc.
  • UCB Pharma, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Epilepsy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Epilepsy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Narrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Narrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Narrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Broad by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Broad by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Broad by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 22: USA Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 28: Canada Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 34: Japan Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 37: China Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 40: China Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 43: Europe Current & Future Analysis for Epilepsy Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Epilepsy Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 52: France Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 55: France Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 58: Germany Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 61: Germany Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 64: Italy Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 67: Italy Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 70: UK Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 73: UK Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 76: Spain Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Spain Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Spain 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 79: Spain Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Spain Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Spain 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 82: Russia Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Russia Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Russia 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 85: Russia Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Russia Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Russia 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 91: Rest of Europe Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 94: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Epilepsy Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 97: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 103: Australia Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Australia Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Australia 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 106: Australia Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Australia Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Australia 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 109: India Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: India Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: India 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 112: India Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: India Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: India 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 115: South Korea Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: South Korea Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: South Korea 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 118: South Korea Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: South Korea Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: South Korea 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 121: Rest of Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Asia-Pacific Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 124: Rest of Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Asia-Pacific Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 127: Latin America Current & Future Analysis for Epilepsy Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 128: Latin America Historic Review for Epilepsy Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Latin America 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 130: Latin America Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Latin America Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Latin America 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 133: Latin America Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Latin America Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Latin America 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 136: Argentina Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Argentina Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Argentina 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 139: Argentina Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Argentina Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Argentina 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 142: Brazil Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Brazil Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Brazil 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 145: Brazil Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Brazil Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Brazil 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 148: Mexico Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Mexico Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Mexico 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 151: Mexico Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Mexico Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Mexico 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 154: Rest of Latin America Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Latin America Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Latin America 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of Latin America Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of Latin America Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of Latin America 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 160: Middle East Current & Future Analysis for Epilepsy Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 161: Middle East Historic Review for Epilepsy Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Middle East 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 163: Middle East Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Middle East Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Middle East 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 166: Middle East Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Middle East Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Middle East 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 169: Iran Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Iran Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Iran 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 172: Iran Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Iran Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Iran 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 175: Israel Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Israel Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Israel 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 178: Israel Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Israel Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Israel 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 181: Saudi Arabia Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Saudi Arabia Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Saudi Arabia 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 184: Saudi Arabia Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Saudi Arabia Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Saudi Arabia 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 187: UAE Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: UAE Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: UAE 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 190: UAE Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: UAE Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: UAE 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 193: Rest of Middle East Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Middle East Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Middle East 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Middle East Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Middle East Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Middle East 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 199: Africa Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Africa Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Africa 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
    • TABLE 202: Africa Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Africa Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Africa 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42